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Many receptors also occur in 
organisms in the natural environment
Effects on behaviour
Rebecca Klaper, Great Lakes Water Institute
Behavioural change – males sitting under tiles, 
not pursuing females. Time spent on breeding 
behaviours was very low.




















‘Nine species of vultures in the 
wild numbered 40 million birds in 
the early 1980s. Today, only 
about 60,000 birds are left’
(Vibhu Prakash, Bombay Natural 
History Society)
Presentation today
• Focus on systems in the UK
• What is the level of exposure at 
the landscape level?
• Could there be impacts?
• Could we manage these impacts?
Monitoring in the UK
• Monthly monitoring of 16 compounds across 
4 catchments










Midlands 402227 17 SAS 1, SB 5, TA 3, TB 8 1.27
Southern England 2071445 81 SAS 12, SB 22, TA 19, TB 28 2.33
Southern England 395581 27 SAS 2, SB 11, TA 8, TB 6 2.42
South East England 177801 14 SAS 2, SB 3, TA 4,TB 5 1.46
SAS - Secondary Activated Sludge; SB - secondary biological filter; TA - Activated Sludge with tertiary treatment;























• 2 Drinking water 
samples
• WwTP influent and 
effluent















DW  250 ng/l
DW  280 ng/l










– 36 pharmaceuticals detected and quantifiable
– 26 pharmaceuticals detected
– 26 pharmaceuticals not detected
• Drinking water
– 6 pharmaceuticals detected: metformin, nicotine, 
acetominophen, carbamazepine, cotinine, 
triamterene
Exposure modelling




Wastewater flow: m3 d-1
River flow: m3 d-1
In-river dissipation rates: d-1
Low Flows 2000 WQX Model
Applied to monitored pharmaceuticals using both the forward 
and inverse modelling approaches
Concentrations of trimethoprim in monitored 
catchments
Predictions for each river reach obtained
using mean, minimum and maximum
removal rates obtained from the inverse
modelling
Assessment of risks across the UK 
landscape
• 22 large catchments across England and 
Wales
• Serving a population of 21 M people
• Predictions obtained for 3117 river 
reaches
• Predictions compared to predicted no 
effect concentrations (and proposed 











Risk to UK Waters

Risk to human health?
• 100 drinking water plants in the modelled 
river network
• Predictions of point of abstraction combined 
with DW treatment removal rates to estimate 
tap water levels
• Assumed individuals consumed 2 L of water 











– 22 week aviary study at environmentally relevant 
exposures
– ADME experiments






































































BCFs soil and species
Soil type Soil pH Soil TOC E. fetida L. terrestris
Clayey loam 6.3 1.89 30.8 66.9
Silty sand 5.1 0.74 20.42 -
Silty sand 6.6 0.97 19.74 -
Clayey loam 7.2 2.99 16.78 -
Clayey sand 7.2 1.23 19.18 -











• 45.5% of modelled river reaches (around 1500 
reaches) have concentrations of ibuprofen of 
potential concern (fish hatching)
• 4.5% of modelled reaches (around 150 reaches) 
have concentrations of diclofenac of concern 
(histological effects)
• Risks to human health is low
• Potential effects on wildlife














Stability of study compounds
17 Pharmaceuticals selected
Decomposition Range 195-704°C




























3 Waste streams: For each 3 Pharmaceutical runs and 2 
control runs
Total of 15 runs: 5 for each waste stream 
Collect all the solids 
(sludge)






Liquid Chromatography Triple 
Quadrupole mass spectrometry
Transformation products
Fourier Transform Mass Spectrometry
Analytical methods
Results - Phase 1
Results - Phase 2
Main results
• Greater than 99% destruction of 
all pharmaceuticals achieved in 
all waste simulations
• No known degradation products 
seen
Summary
• Major concerns over pharmaceuticals in the 
environment
• Using combination of modelling and monitoring we 
now have a good understanding of exposure of 
pharmaceuticals of concern
• A significant proportion of river reaches in the UK may 
be at risk so some compounds require further scrutiny
• Impacts on wildlife also possible
• A range of management options available - there is a 
need for an integrated approach
• Still many open questions
iPiE
• IMI project
• 10.3 M Euro project over 4 years
• Started 1 January 2015
• 25 partners from industry, academia, research 
institution and regulators
46
iPiE – The Aim
To develop frameworks that utilize information from 
toxicological studies, pharmacological mode of 
action and in silico models to support intelligence-
based environmental testing of pharmaceuticals in 
development and to prioritise legacy 
pharmaceuticals for targeted environmental risk 
assessment and/or environmental (bio) monitoring.
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